Professor Stephen Clarke OAM

Professor of Medicine
Medicine, Northern Clinical School
Kolling Institute of Medical Research

E25 - Royal North Shore Hospital
The University of Sydney
NSW 2006 Australia

T: +61 2 9926 5048 / 7494
F: +61 2 9767 7603

Research interests

Cancer pharmacology, colorectal cancer, lung cancer

Current national competitive grants*


Ginkgo biloba preserves cognitive function in women treated with adjuvant chemotherapy for early breast cancer: a double-blind, placebo-controlled, randomised phase III trial
Vardy J, Dhillon H, Bell M, Cysique L, Boyle F, Clarke S
Cancer Australia Priority-driven Collaborative Cancer Research Scheme ($600,000 over 3 years)

* Grants administered through the University of Sydney


Pharmacology; Nutrition and metabolism; Lung cancer; Cancer; Bowel cancer

International links

China. (Renji Hospital and Shanghai Jiaotong University) Clinical trial of ethnic differences in tolerability of chemotherapy.


2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009


  • Kao, S., van Zandwijk, N., Clarke, S., Vardy, J., Lumba, S., Tognela, A., Ng, W. (2015), Estimation of an optimal chemotherapy utilization rate for malignant pleural mesothelioma: An evidence-based benchmark for cancer care. Asia-Pacific Journal of Clinical Oncology. 11, 85-92. [Abstract]
  • Zhou, J., Belov, L., Chapuis, P., Chan, C., Armstrong, N., Kaufman, K., Solomon, M., Clarke, S., Christopherson, R. (2015), Surface profiles of live colorectal cancer cells and tumor infiltrating lymphocytes from surgical samples correspond to prognostic categories. Journal of immunological methods. 416, 59-68. [Abstract]
  • Michael, M., White, S., Abdi, E., Nott, L., Clingan, P., Zimet, A., Button, P., Gregory, D., Solomon, B., Dobrovic, A., Do, H., Clarke, S. (2015), Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC. Asia-Pacific Journal of Clinical Oncology. 11(1), 4-14. [Abstract]


  • Kohonen-Corish, M., Tseung, J., Chan, C., Currey, N., Dent, O., Clarke, S., Bokey, L., Chapuis, P. (2014), KRAS mutations and CDKN2A promoter methylation show an interactive adverse effect on survival and predict recurrence of rectal cancer. International Journal of Cancer. 134(12), 2820-2828. [Abstract]
  • Kim, B., Li, B., Engel, A., Samra, J., Clarke, S., Norton, I., Li, A. (2014), Diagnosis of gastrointestinal bleeding: A practical guide for clinicians. World Journal of Gastrointestinal Pathophysiology. 5(4), 467-478. [Abstract]
  • Diakos, C., Charles, K., McMillan, D., Clarke, S. (2014), Cancer-related inflammation and treatment effectiveness. The Lancet. Oncology. 15(11), e493-e503. [Abstract]
  • Vardy, J., Dhillon, H., Pond, G., Rourke, S., Xu, W., Dodd, A., Renton, C., Park, A., Bekele, T., Ringash, J., Zhang, H., Burkes, R., Clarke, S., Tannock, I. (2014), Cognitive function and fatigue after diagnosis of colorectal cancer. Annals of Oncology. 25(12), 2404-2412. [Abstract]
  • Linton, A., Pavlakis, N., O'Connell, R., Soeberg, M., Kao, S., Clarke, S., Vardy, J., van Zandwijk, N. (2014), Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales. British Journal of Cancer. 111(9), 1860-1869. [Abstract]
  • Wang, F., Gill, A., Neale, M., Puttaswamy, V., Gananadha, S., Pavlakis, N., Clarke, S., Hugh, T., Samra, J. (2014), Adverse tumor biology associated with mesenterico-portal vein resection influences survival in patients with pancreatic ductal adenocarcinoma. Annals of Surgical Oncology. 21(6), 1937-1947. [Abstract]
  • Chik, J., Zhou, J., Moh, E., Christopherson, R., Clarke, S., Molloy, M., Packer, N. (2014), Comprehensive glycomics comparison between colon cancer cell cultures and tumours: Implications for biomarker studies. Journal of Proteomics. 108(C), 146-162. [Abstract]
  • Weir, C., Hudson, A., Moon, E., Ross, A., Alexander, M., Peters, L., Langova, V., Clarke, S., Pavlakis, N., Davey, R., Howell, V. (2014), Streptavidin: a novel immunostimulant for the selection and delivery of autologous and syngeneic tumor vaccines. Cancer Immunology Research. 2(5), 469-479. [Abstract]
  • Kao, S., van Zandwijk, N., Clarke, S. (2014), Comment on 'Neutrophil to lymphocyte ratio in malignant pleural mesothelioma'. British Journal of Cancer. , 2376. [Abstract]
  • Hayes, S., Hudson, A., Clarke, S., Molloy, M., Howell, V. (2014), From mice to men: GEMMs as trial patients for new NSCLC therapies. Seminars in Cell & Developmental Biology. 27, 118-127. [Abstract]
  • Sonpavde, G., Pond, G., Armstrong, A., Clarke, S., Vardy, J., Templeton, A., Wang, S., Paolini, J., Chen, I., Chow-Maneval, E., Lechuga, M., Smith, M., Michaelson, M. (2014), Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Men With Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer. 12(5), 317-324. [Abstract]
  • Hudson, A., Weir, C., Moon, E., Harvie, R., Klebe, S., Clarke, S., Pavlakis, N., Howell, V. (2014), Establishing a panel of chemo-resistant mesothelioma models for investigating chemo-resistance and identifying new treatments for mesothelioma. Scientific Reports. 4, 6152. [Abstract]
  • Tsoli, M., Schweiger, M., Vanniasinghe, A., Painter, A., Zechner, R., Clarke, S., Robertson, G. (2014), Depletion of white adipose tissue in cancer cachexia syndrome is associated with inflammatory signaling and disrupted circadian regulation. PloS One. 9(3), e92966. [Abstract]


  • de Marinis, F., Passaro, A., Clarke, S. (2013), Vitamin supplementation in patients receiving pemetrexed for advanced non-small cell lung cancer. Lung Cancer. , 511. [Abstract]
  • Vardy, J., Dhillon, H., Clarke, S., Olesen, I., Leslie, F., Warby, A., Beith, J., Sullivan, A., Hamilton, A., Beale, P., Rittau, A., McLachlan, A. (2013), Investigation of herb-drug interactions with ginkgo biloba in women receiving hormonal treatment for early breast cancer. SpringerPlus. 2(1), 126. [Abstract]
  • Linton, A., Kao, S., Vardy, J., Clarke, S., van Zandwijk, N., Klebe, S. (2013), Immunohistochemistry in the diagnosis of malignant pleural mesothelioma: Trends in Australia and a literature review. Asia-Pacific Journal of Clinical Oncology. 9(3), 273-279. [Abstract]
  • Kao, S., Lee, K., Klebe, S., Henderson, D., McCaughan, B., Vardy, J., Clarke, S., van Zandwijk, N. (2013), Excision Repair Cross Complementation Group 1 and Thymidylate Synthase Expression in Patients With Mesothelioma. Clinical Lung Cancer. 14(2), 164-171. [Abstract]
  • Guthrie, G., Charles, K., Roxburgh, C., Horgan, P., McMillan, D., Clarke, S. (2013), The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Critical Reviews in Oncology/Hematology. 88(1), 218-230. [Abstract]
  • Kao, S., Vardy, J., Harvie, R., Chatfield, M., van Zandwijk, N., Clarke, S., Pavlakis, N. (2013), Health-related quality of life and inflammatory markers in malignant pleural mesothelioma. Supportive Care in Cancer. 21(3), 697-705. [Abstract]
  • Kao, S., Clarke, S., Vardy, J., Corte, P., Clarke, C., van Zandwijk, N. (2013), Patterns of care for malignant pleural mesothelioma patients compensated by the Dust Diseases Board in New South Wales of Australia. Internal Medicine Journal. 43(4), 402-410. [Abstract]
  • Stein, R., Sharpe, L., Bell, M., Boyle, F., Dunn, S., Clarke, S. (2013), Randomized Controlled Trial of a Structured Intervention to Facilitate End-of-Life Decision Making in Patients With Advanced Cancer. Journal of Clinical Oncology. 31(27), 3403-3410. [Abstract]
  • Linton, A., Pond, G., Clarke, S., Vardy, J., Galsky, M., Sonpavde, G. (2013), Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. Clinical Genitourinary Cancer. 11(4), 423-430. [Abstract]
  • Toon, C., Walsh, M., Chou, A., Capper, D., Clarkson, A., Sioson, L., Clarke, S., Mead, S., Walters, R., Clendenning, M., Rosty, C., Young, J., Win, A., Hopper, J., Crook, A., von Deimling, A., Jenkins, M., Buchanan, D., Gill, A. (2013), BRAFV600E Immunohistochemistry Facilitates Universal Screening of Colorectal Cancers for Lynch Syndrome. The American Journal of Surgical Pathology. 37(10), 1592-1602. [Abstract]
  • Kao, S., Vardy, J., Chatfield, M., Corte, P., Pavlakis, N., Clarke, C., van Zandwijk, N., Clarke, S. (2013), Validation of Prognostic Factors in Malignant Pleural Mesothelioma: A Retrospective Analysis of Data From Patients Seeking Compensation From the New South Wales Dust Diseases Board. Clinical Lung Cancer. 14(1), 70-77. [Abstract]
  • Kacevska, M., Mahns, A., Sharma, R., Clarke, S., Robertson, G., Liddle, C. (2013), Extra-Hepatic Cancer Represses Hepatic Drug Metabolism Via Interleukin (IL)-6 Signalling. Pharmaceutical Research. 30(9), 2270-278. [Abstract]
  • Elens, L., Nieuweboer, A., Clarke, S., Charles, K., de Graan, A., Haufroid, V., van Gelder, T., Mathijssen, R., van Schaik, R. (2013), Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin. Pharmacogenetics and Genomics. 23(3), 148-155. [Abstract]
  • Kao, S., van Zandwijk, N., Corte, P., Clarke, C., Clarke, S., Vardy, J. (2013), Use of cancer therapy at the end of life in patients with malignant pleural mesothelioma. Supportive Care in Cancer. 21(7), 1879-1884. [Abstract]
  • Clarke, S., Karapetis, C., Gibbs, P., Pavlakis, N., Desai, J., Michael, M., Tebbutt, N., Price, T., Tabernero, J. (2013), Overview of biomarkers in metastatic colorectal cancer: tumour, blood and patient-related factors. Critical Reviews in Oncology/Hematology. 85(2), 121-135. [Abstract]
  • Elens, L., Nieuweboer, A., Clarke, S., Charles, K., de Graan, A., Haufroid, V., Mathijssen, R., van Schaik, R. (2013), CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. Pharmacogenomics. 14(2), 137-149. [Abstract]
  • Clarke, S., Burge, M., Cordwell, C., Gibbs, P., Reece, W., Tebbutt, N. (2013), An Australian translational Study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastinâ¿¢) [ASCENT]. BMC Cancer. 13, 120. [Abstract]
  • Hibbert, E., Lambert, T., Carter, J., Learoyd, D., Twigg, S., Clarke, S. (2013), A randomized controlled pilot trial comparing the impact of access to clinical endocrinology video demonstrations with access to usual revision resources on medical student performance of clinical endocrinology skills. BMC Medical Education. 13, 135. [Abstract]
  • Findlay, M., Bauer, J., Clarke, S., Isenring, E. (2013), Understanding nutritional issues in the older person with cancer. Cancer Forum. 37:3, 234-237.
  • Jankova, L., Dent, O., Chan, C., Chapuis, P., Clarke, S. (2013), Preoperative neutrophil/lymphocyte ratio predicts overall survival but does not predict recurrence or cancer-specific survival after curative resection of node-positive colorectal cancer. BMC Cancer. 13, 442. [Abstract]


  • Bullen, T., Sharpe, L., Lawsin, C., Patel, D., Clarke, S., Bokey, L. (2012), Body image as a predictor of psychopathology in surgical patients with colorectal disease. Journal of Psychosomatic Research. 73(6), 459-463. [Abstract]
  • Randall, S., McKay, M., Pascovici, D., Mahon, K., Horvath, L., Clarke, S., Molloy, M. (2012), Remarkable temporal stability of high-abundance human plasma proteins assessed by targeted mass spectrometry. Proteomics. Clinical Applications. 6(11-12), 626-634. [Abstract]
  • de Gramont, A., Van Cutsem, E., Schmoll, H., Tabernero, J., Clarke, S., Moore, M., Cunningham, D., Cartwright, T., Hecht, J., Rivera, F., Im, S., Bodoky, G., Salazar, R., Maindrault-Goebel, F., Shacham-Shmueli, E., Bajetta, E., Makrutzki, M., Shang, A., André, T., Hoff, P. (2012), Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. The Lancet Oncology. 13(12), 1225-1233. [Abstract]
  • Clarke, S., McLachlan, A. (2012), Interaction Between Complementary and Alternative Medicines and Conventional Medicines. In: Perspectives on Complementary and Alternative Medicine. (pp.227-261).United Kingdom: Imperial College Press.
  • Michael, M., Pavlakis, N., Clingan, P., De Boer, R., Johnston, M., Clarke, S. (2012), A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer. Oncology Reports. 28(3), 763-767. [Abstract]
  • Davis, E., Oh, B., Butow, P., Mullan, B., Clarke, S. (2012), Cancer Patient Disclosure and Patient-Doctor Communication of Complementary and Alternative Medicine Use: A Systematic Review. The Oncologist. 17(11), 1475-1481. [Abstract]
  • Proctor, M., McMillan, D., Morrison, D., Fletcher, C., Horgan, P., Clarke, S. (2012), A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. British Journal of Cancer. 107(4), 695-699. [Abstract]
  • Chua, W., Clarke, S., Charles, K. (2012), Systemic inflammation and prediction of chemotherapy outcomes in patients receiving docetaxel for advanced cancer. Supportive Care in Cancer. 20(8), 1869-1874. [Abstract]
  • Tsoli, M., Moore, M., Burg, D., Painter, A., Taylor, R., Lockie, S., Turner, N., Warren, A., Cooney, G., Oldfield, B., Clarke, S., Robertson, G. (2012), Activation of thermogenesis in brown adipose tissue and dysregulated lipid metabolism associated with cancer cachexia in mice. Cancer Research. 72(17), 4372-4382. [Abstract]
  • Oh, B., Butow, P., Mullan, B., Hale, A., Lee, M., Guo, X., Clarke, S. (2012), A Critical Review of the Effects of Medical Qigong on Quality of Life, Immune Function, and Survival in Cancer Patients. Integrative Cancer Therapies. 11(2), 101-110. [Abstract]
  • Oh, B., Butow, P., Mullan, B., Clarke, S., Beale, P., Pavlakis, N., Lee, M., Rosenthal, D., Larkey, L., Vardy, J. (2012), Effect of medical Qigong on cognitive function, quality of life, and a biomarker of inflammation in cancer patients: a randomized controlled trial. Supportive Care in Cancer. 20(6), 1235-1242. [Abstract]
  • Kho, P., Jankova, L., Fung, C., Chan, C., Clarke, C., Lin, B., Robertson, G., Molloy, M., Chapuis, P., Bokey, E., Dent, O., Clarke, S. (2012), Overexpression of protein S100A4 is independently associated with overall survival in stage C colonic cancer but only in cytoplasm at the advancing tumour front. International Journal of Colorectal Disease. 27(11), 1409-1417. [Abstract]
  • Clarey, J., Kao, S., Clarke, S., Vardy, J. (2012), The eligibility of advanced non-small-cell lung cancer patients for targeted therapy clinical trials. Annals of Oncology. 23(5), 1229-1233. [Abstract]
  • Kho, P., Chapuis, P., Beale, P., Bokey, L., Dent, O., Clarke, S. (2012), Use of adjuvant chemotherapy in stage C (III) rectal cancer: Comparison of data from matched patients in a teaching hospital's clinico-pathological database. Asia-Pacific Journal of Clinical Oncology. 8(4), 346-355. [Abstract]
  • Hasovits, C., Clarke, S. (2012), Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics. Clinical Pharmacokinetics. 51(4), 203-224. [Abstract]
  • Chua, W., Horvath, L., Beale, P., Clarke, S. (2012), Reporting clinical trial information: colorectal cancer trials at Sydney Cancer Centre. Internal Medicine Journal. 42(4), 416-421. [Abstract]
  • Linton, A., Vardy, J., Clarke, S., van Zandwijk, N. (2012), The ticking time-bomb of asbestos: Its insidious role in the development of malignant mesothelioma. Critical Reviews in Oncology/Hematology. 84(2), 200-212. [Abstract]
  • Chellappa, K., Jankova, L., Schnabl, J., Pan, S., Brelivet, Y., Fung, C., Chan, C., Dent, O., Clarke, S., Robertson, G., Sladek, F. (2012), Src tyrosine kinase phosphorylation of nuclear receptor HNF4? correlates with isoform-specific loss of HNF4? in human colon cancer. Proceedings of the National Academy of Sciences of the United States of America. 109(7), 2302-2307. [Abstract]
  • Kao, S., Harvie, R., Paturi, F., Taylor, R., Davey, R., Abraham, R., Clarke, S., Marx, G., Cullen, M., Kerestes, Z., Pavlakis, N. (2012), The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine. Lung Cancer. 75(2), 248-254. [Abstract]
  • Shum, A., Mahendradatta, T., Taylor, R., Painter, A., Moore, M., Tsoli, M., Tan, T., Clarke, S., Robertson, G., Polly, P. (2012), Disruption of MEF2C signaling and loss of sarcomeric and mitochondrial integrity in cancer-induced skeletal muscle wasting. Aging. 4(2), 133-143. [Abstract]
  • Michael, M., Cullinane, C., Hatzimihalis, A., O'Kane, C., Milner, A., Booth, R., Schlicht, S., Clarke, S., Francis, P. (2012), Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C(14)-erythromycin breath test and the antipyrine clearance test. Cancer chemotherapy and pharmacology. 69(1), 125-35. [Abstract]
  • Jankova, L., Robertson, G., Chan, C., Tan, K., Kohonen-Corish, M., Fung, C., Clarke, C., Lin, B., Molloy, M., Chapuis, P., Bokey, L., Dent, O., Clarke, S. (2012), Glutathione S-transferase Pi expression predicts response to adjuvant chemotherapy for stage C colon cancer: a matched historical control study. BMC Cancer. 12, 196. [Abstract]
  • Dhillon, H., van der Ploeg, H., Bell, M., Boyer, M., Clarke, S., Vardy, J. (2012), The impact of physical activity on fatigue and quality of life in lung cancer patients: a randomised controlled trial protocol. BMC Cancer. 12, 572. [Abstract]
  • Hasovits, C., Pavlakis, N., Howell, V., Gill, A., Clarke, S. (2012), Resistance to EGFR targeted antibodies- expansion of clones present from the start of treatment. The more things change, the more they stay the same (Plus ca change, plus ca ne change pas!). Translational Gastrointestinal Cancer. 12, 627.


  • Mitchell, P., Broad, A., Rosenthal, M., Galettis, P., Abraham, R., Burns, I., Clarke, S., Milner, A., Diiulio, J., Links, M. (2011), Randomized phase 2 sequencing and pharmacokinetic study of gemcitabine and oxaliplatin in advanced non-small cell lung cancer. Asia Pacific Journal of Clinical Oncology. 7(4), 376-384. [Abstract]
  • Tan, K., Jankova, L., Chan, C., Fung, C., Clarke, C., Lin, B., Robertson, G., Molloy, M., Chapuis, P., Bokey, L., Dent, O., Clarke, S. (2011), Clinicopathological correlates and prognostic significance of glutathione S-transferase Pi expression in 468 patients after potentially curative resection of node-positive colonic cancer. Histopathology. 59(6), 1057-1070. [Abstract]
  • Phan, V., Tan, C., Rittau, A., Xu, H., McLachlan, A., Clarke, S. (2011), An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs. Expert opinion on drug metabolism & toxicology. 7(11), 1395-410. [Abstract]
  • Jankova, L., Chan, C., Fung, C., Song, X., Kwun, S., Cowley, M., Kaplan, W., Dent, O., Bokey, E., Chapuis, P., Baker, M., Robertson, G., Clarke, S., Molloy, M. (2011), Proteomic comparison of colorectal tumours and non-neoplastic mucosa from paired patient samples using iTRAQ mass spectrometry. Molecular bioSystems. 7(11), 2997-3005. [Abstract]
  • Kao, S., Klebe, S., Henderson, D., Reid, G., Chatfield, M., Armstrong, N., Yan, T., Vardy, J., Clarke, S., van Zandwijk, N., McCaughan, B. (2011), Low Calretinin Expression and High Neutrophil-To-Lymphocyte Ratio Are Poor Prognostic Factors in Patients with Malignant Mesothelioma Undergoing Extrapleural Pneumonectomy. Journal of Thoracic Oncology. 6(11), 1923-1929. [Abstract]
  • Lee, A., Chick, J., Kolarich, D., Haynes, P., Robertson, G., Tsoli, M., Jankova, L., Clarke, S., Packer, N., Baker, M. (2011), Liver membrane proteome glycosylation changes in mice bearing an extra-hepatic tumour. Molecular & cellular proteomics : MCP. 10(9), M900538MCP200. [Abstract]
  • Clarke, S., Chua, W., Moore, M., Kao, S., Phan, V., Tan, C., Charles, K., McMillan, D. (2011), Use of inflammatory markers to guide cancer treatment. Clinical Pharmacology and Therapeutics. 90(3), 475-478. [Abstract]
  • Chua, W., Kho, P., Moore, M., Charles, K., Clarke, S. (2011), Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer. Critical reviews in oncology/hematology. 79(3), 224-50. [Abstract]
  • Clarke, S., Yip, S., Brown, C., van Hazel, G., Ransom, D., Goldstein, D., Jeffrey, G., Tebbut, N., Buck, M., Lowenthal, R., Boland, A., Gebski, V., Zalcberg, J., Simes, R. (2011), Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis. European journal of cancer (Oxford, England : 1990). 47(12), 1826-36. [Abstract]
  • Cassidy, J., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Rittweger, K., Gilberg, F., Saltz, L. (2011), XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. British Journal of Cancer. 105(1), 58-64. [Abstract]
  • Patel, D., Sharpe, L., Thewes, B., Bell, M., Clarke, S. (2011), Using the distress thermometer and hospital anxiety and depression scale to screen for psychosocial morbidity in patients diagnosed with colorectal cancer. Journal of affective disorders. 131(1-3), 412-6. [Abstract]
  • Kao, S., Griggs, K., Lee, K., Armstrong, N., Clarke, S., Vardy, J., van Zandwijk, N., Burn, J., McCaughan, B., Henderson, D., Klebe, S. (2011), Validation of a minimal panel of antibodies for the diagnosis of malignant pleural mesothelioma. Pathology. 43(4), 313-7. [Abstract]
  • Leighl, N., Shepherd, H., Butow, P., Clarke, S., McJannett, M., Beale, P., Wilcken, N., Moore, M., Chen, E., Goldstein, D., Horvath, L., Knox, J., Krzyzanowska, M., Oza, A., Feld, R., Hedley, D., Xu, W., Tattersall, M. (2011), Supporting Treatment Decision Making in Advanced Cancer: A Randomized Trial of a Decision Aid for Patients With Advanced Colorectal Cancer Considering Chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(15), 2077-84. [Abstract]
  • Kacevska, M., Downes, M., Sharma, R., Evans, R., Clarke, S., Liddle, C., Robertson, G. (2011), Extrahepatic Cancer Suppresses Nuclear Receptor-Regulated Drug Metabolism. Clinical cancer research : an official journal of the American Association for Cancer Research. 17(10), 3170-80. [Abstract]
  • Sharpe, L., Patel, D., Clarke, S. (2011), The relationship between body image disturbance and distress in colorectal cancer patients with and without stomas. Journal of Psychosomatic Research. 70(5), 395-402. [Abstract]
  • Backshall, A., Sharma, R., Clarke, S., Keun, H. (2011), Pharmacometabonomic Profiling as a Predictor of Toxicity in Patients with Inoperable Colorectal Cancer Treated with Capecitabine. Clinical cancer research : an official journal of the American Association for Cancer Research. 17(9), 3019-28. [Abstract]
  • Chua, W., Charles, K., Baracos, V., Clarke, S. (2011), Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. British Journal of Cancer. 104(8), 1288-1295. [Abstract]
  • Kao, S., Yan, T., Lee, K., Burn, J., Henderson, D., Klebe, S., Kennedy, C., Vardy, J., Clarke, S., van Zandwijk, N., McCaughan, B. (2011), Accuracy of Diagnostic Biopsy for the Histological Subtype of Malignant Pleural Mesothelioma. Journal of Thoracic Oncology. 6(3), 602-605. [Abstract]
  • Kao, S., Lee, K., Armstrong, N., Clarke, S., Vardy, J., van Zandwijk, N., Reid, G., Burn, J., McCaughan, B., Henderson, D., Klebe, S. (2011), Validation of tissue microarray technology in malignant pleural mesothelioma. Pathology. 43(2), 128-132. [Abstract]
  • Fung, D., Lo, A., Jankova, L., Clarke, S., Molloy, M., Robertson, G., Wilkins, M. (2011), Classification of Cancer Patients Using Pathway Analysis and Network Clustering. In: Methods in Molecular Biology: Network Biology Methods and Applications. (pp.311-336).United States: Springer.
  • He, X., Clarke, S., McLachlan, A. (2011), Clinical pharmacology of chemotherapy agents in older people with cancer. Current Gerontology and Geriatrics Research. 2011, 628670. [Abstract]
  • Oh, B., Hu, G., Kao, S., Gebski, V., Walls, R., Truong, L., Beale, P., Clarke, S. (2011), Safety and tolerability of Chinese Herbal Medicine with cancer patients receiving chemotherapy. WebmedCentral. 2(3), WMC001671.
  • Clarke, S., McLachlan, A. (2011), Interaction between complementary and alternative medicine with conventional anti-cancer medicine. Cancer Forum. 35:1, 18-23.
  • Zhou, J., Belov, L., Solomon, M., Chan, C., Clarke, S., Christopherson, R. (2011), Colorectal cancer cell surface protein profiling using an antibody microarray and fluorescence multiplexing. Journal of Visualized Experiments. 0(55), 3322. [Abstract]


  • Oh, B., Butow, P., Mullan, B., Beale, P., Pavlakis, N., Rosenthal, D., Clarke, S. (2010), The use and perceived benefits resulting from the use of complementary and alternative medicine by cancer patients in Australia. Asia-Pacific journal of clinical oncology. 6(4), 342-349. [Abstract]
  • Kao, S., Pavlakis, N., Harvie, R., Vardy, J., Boyer, M., van Zandwijk, N., Clarke, S. (2010), High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clinical Cancer Research. 16(23), 5805-5813. [Abstract]
  • Kao, S., Reid, G., Lee, K., Vardy, J., Clarke, S., van Zandwijk, N. (2010), Malignant Mesothelioma. Internal Medicine Journal. 40(11), 742-750. [Abstract]
  • Blinman, P., Duric, V., Nowak, A., Beale, P., Clarke, S., Briscoe, K., Boyce, A., Goldstein, D., Hudson, M., Stockler, M. (2010), Adjuvant chemotherapy for early colon cancer: What survival benefits make it worthwhile?. European journal of cancer (Oxford, England : 1990). 46(10), 1800-7. [Abstract]
  • Matic, M., Corradin, A., Tsoli, M., Clarke, S., Polly, P., Robertson, G. (2010), The alternatively spliced murine pregnane X receptor isoform, mPXR(Delta171-211) exhibits a repressive action. The International Journal of Biochemistry & Cell Biology. 42(5), 672-682. [Abstract]
  • Chua, W., Clarke, S. (2010), Clinical trial information as a measure of quality cancer care. Journal of Oncology Practice. 6(3), 170-171. [Abstract]
  • Chan, C., Jankova, L., Fung, C., Clarke, C., Robertson, G., Chapuis, P., Bokey, L., Lin, B., Dent, O., Clarke, S. (2010), Fascin Expression Predicts Survival After Potentially Curative Resection of Node-positive Colon Cancer. The American journal of surgical pathology. 34(5), 656-66. [Abstract]
  • Zhou, J., Belov, L., Huang, P., Shin, J., Solomon, M., Chapuis, P., Bokey, L., Chan, C., Clarke, C., Clarke, S., Christopherson, R. (2010), Surface antigen profiling of colorectal cancer using antibody microarrays with fluorescence multiplexing. Journal of Immunological Methods. 355(1-2), 40-51. [Abstract]
  • Moore, M., Chua, W., Charles, K., Clarke, S. (2010), Inflammation and cancer: causes and consequences. Clinical Pharmacology and Therapeutics. 87(4), 504-508. [Abstract]
  • Oh, B., Butow, P., Mullan, B., Clarke, S., Beale, P., Pavlakis, N., Kothe, E., Lam, L., Rosenthal, D. (2010), Impact of Medical Qigong on quality of life, fatigue, mood and inflammation in cancer patients: a randomized controlled trial. Annals of Oncology. 21(3), 608-614. [Abstract]
  • Fung, C., Chan, C., Jankova, L., Dent, O., Robertson, G., Molloy, M., Bokey, L., Chapuis, P., Lin, B., Clarke, S. (2010), Clinicopathological correlates and prognostic significance of maspin expression in 450 patients after potentially curative resection of node-positive colonic cancer. Histopathology. 56(3), 319-330. [Abstract]
  • Kho, P., Chua, W., Moore, M., Clarke, S. (2010), Is it prime time for personalized medicine in cancer treatment?. Personalized Medicine. 7(4), 387-397.
  • Lam, F., Jankova, L., Dent, O., Molloy, M., Kwun, S., Clarke, C., Chapuis, P., Robertson, G., Beale, P., Clarke, S., Bokey, L., Chan, C. (2010), Identification of distinctive protein expression patterns in colorectal adenoma. PROTEOMICS - Clinical Applications. 4(1), 60-70.
  • Clarke, S., McLachlan, A., Brown, D., Cabonara, S., Kissane, R. (2010), Beyond Conventional Cancer Treatments: The Use of Complementary Therapies During Cancer Treatment: Implications for Clinicians. In: When Cancer Crosses Disciplines: A Physician's Handbook. (pp.285-315).London, UK: Imperial College Press.
  • Oh, B., Butow, P., Mullan, B., Clarke, S., Tattersall, M., Boyer, M., Beale, P., Vardy, J., Pavlakis, N., Larke, L. (2010), Patient-doctor communication: use of complementary and alternative medicine by adult patients with cancer. Journal of the Society for Integrative Oncology. 8(2), 56-64. [Abstract]
  • Kao, S., Butow, P., Bray, V., Clarke, S., Vardy, J. (2010), Patient and oncologist estimates of survival in advanced cancer patients. Psycho-Oncology. 0, 0.
  • Kao, S., Phan, V., Clarke, S. (2010), Predictive Markers for Haematological Toxicity of Pemetrexed. Current drug targets. 11(1), 48-57. [Abstract]


  • Chua, W., Moore, M., Charles, K., Clarke, S. (2009), Predictive biomarkers of clinical response to targeted antibodies in colorectal cancer. Current Opinion in Molecular Therapeutics. 11(6), 611-622. [Abstract]
  • Chapuis, P., Bokey, E., Clarke, S., Beale, P., Dent, O. (2009), Adjuvant chemotherapy for stage C colonic cancer in a multidisciplinary setting. ANZ Journal of Surgery. 79(10), 685-692. [Abstract]
  • Chua, W., Goldstein, D., Lee, C., Dhillon, H., Michael, M., Mitchell, P., Clarke, S., Iacopetta, B. (2009), Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. British Journal of Cancer. 101(6), 998-1004. [Abstract]
  • Chua, W., Peters, M., Loneragan, R., Clarke, S. (2009), Cetuximab-associated pulmonary toxicity. Clinical colorectal cancer. 8(2), 118-120. [Abstract]
  • Phan, V., Moore, M., McLachlan, A., Piquette-Miller, M., Xu, H., Clarke, S. (2009), Ethnic differences in drug metabolism and toxicity from chemotherapy. Expert Opinion on Drug Metabolism & Toxicology. 5(3), 243-257. [Abstract]
  • Vardy, J., Dadasovich, R., Beale, P., Boyer, M., Clarke, S. (2009), Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials. BMC cancer. 9(1), 130. [Abstract]
  • Sharma, R., Cunningham, D., Smith, P., Robertson, G., Dent, O., Clarke, S. (2009), Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients--analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO. BMC Cancer. 9, 153. [Abstract]
  • Matic, M., Nakhel, S., Lehnert, A., Polly, P., Clarke, S., Robertson, G. (2009), A novel approach to investigate the subcellular distribution of nuclear receptors in vivo. Nuclear Receptor Signaling. 7(0), e004. [Abstract]
  • Sobrero, A., Ackland, S., Clarke, S., Perez-Carrion, R., Chiara, S., Gapski, J., Mainwaring, P., Langer, B., Young, S. (2009), Phase IV Study of Bevacizumab in Combination with Infusional Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in First-Line Metastatic Colorectal Cancer. Oncology. 77(2), 113-119. [Abstract]